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A new family of guanidinium-rich molecular transporters featuring a novel oligocarbonate backbone
with 1,7-sidechain spacing is described. Conjugates can be rapidly assembled irrespective of length
in a one step oligomerization strategy that can proceed with concomitant introduction of probes (or
by analogy drugs). The new transporters exhibit excellent cellular entry as determined by flow
cytometry and fluorescence microscopy, and the functionality of their drug delivery capabilities was
confirmed by the delivery of the bioluminescent small molecule probe luciferin and turnover by its
intracellular target enzyme.
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New strategies, devices and agents that enable or enhance the passage of drugs or probes across
biological barriers are required to address a range of major challenges in chemotherapy,
imaging, diagnostics, and mechanistic chemical biology.1 In 2000, we reported that the cellular
uptake of the Tat49–57 peptide could be mimicked by homooligomers of arginine.2 Uptake was
shown to be a function of the number and array of guanidinium groups, observations that led
to the design and synthesis of the first guanidinium-rich (GR) peptoids,2 GR-spaced peptides,
3 GR-oligocarbamates4 and GR-dendrimeric molecular transporters (MoTrs).5 Noteworthy
subsequent studies from several groups showed that a variety of other scaffolds, including betapeptides, carbohydrates, heterocycles, and peptide nucleic acids, upon perguanidinylation,
exhibit cell-penetrating activity.6 GR MoTrs have been shown to carry a variety of cargos into
cells, including small molecules, probes, metals, peptides, proteins, siRNA, morpholinoRNAs, and DNA plasmids.7 Activatable MoTrs have been reported for targeted therapy and
imaging,8 a releasable octaarginine-drug conjugate has been shown to overcome Pgp-mediated
resistance in animal models of cancer,9 and a drug-heptaarginine conjugate has been advanced
to phase II human clinical trials.10
Correspondence to: James L. Hedrick; Robert M. Waymouth; Paul A. Wender, wenderp@stanford.edu.
Supporting Information Available: Experimental procedures, flow cytometry and concentration dependent uptake data, NMR data and
fluorescence microscopy images. This material is available free of charge via the internet at http://pubs.acs.org.
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While octaarginine MoTrs have been made on scale under GMP conditions and a step-saving
segment doubling approach has been introduced,11 the length and associated costs of these
syntheses preclude some anticipated applications. A solid phase synthesis of octaarginine
requires ≥16 steps, while the segment doubling approach involves 9 steps.11 We report herein
a new family of oligocarbonate GR MoTrs that can be flexibly and efficiently assembled in a
one-step organocatalytic ring opening oligomerization process that also allows for concomitant
probe (or drug) attachment and control over transporter length.
We have previously shown that a metal-free, organocatalytic ring-opening polymerization
(ROP)12 of cyclic carbonates13 initiated by a variety of nucleophiles, including alcohols,
amines and thiols, provides narrowly dispersed polymers of predictable molecular weights and
end-group fidelity.14 We reasoned that if cyclic carbonates incorporating a guanidinium side
chain could be used in this process, and if the initiator could be a drug or probe, then one-step
assembly of oligocarbonate MoTr-drug or -probe conjugates could be realized. Significantly,
unlike solid or solution phase syntheses of oligomeric MoTrs in which step count increases
with transporter length, this controlled catalytic oligomerization strategy would provide access
to various lengths in one step simply through adjustment of the initiator-monomer ratio.15
Moreover, the metal-free nature of the catalysts and low catalyst loadings (typically 5%) are
anticipated to avoid the cytotoxicity associated with catalyst residues.
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The new guanidine-protected monomer 3 was prepared by coupling the cyclic carbonate 1 and
1,3-di-Boc-2-(2-hydroxyethyl) guanidine 2. It is noteworthy that alcohol 2 does not initiate
oligomerization of monomer 3 in the absence of catalyst. However, when the alcohol-tagged
dansyl fluorophore initiator 4a or protected sulfur alcohol 4b (Scheme 1) is mixed with
monomer 3 in the presence of the bifunctional thiourea/amine catalyst TU/DBU,16 ring opening
oligomerization readily occurs. This catalyst exhibits exquisite selectivity for ring-opening
oligomerization; no transesterification is observed. This exquisite control stems from the high
selectivity of this catalyst combination towards the strained cyclic carbonate of the monomer
relative to the acyclic carbonate and ester moieties of the oligomers.14,16 Moreover, oligomers
of various lengths are generated by simply controlling the monomer-to-initiator ratio ([M]o/
[I]o). Oligomers 5a–e exhibit well defined molecular weights and narrow polydispersities
(Mn = 3,800, 5,200, 10,000, 3,900, 5,100; Mw/Mn = 1.16, 1.11, 1.15, 1.16, 1.16, respectively).
With a 5 mol % catalyst loading ([M]0 = 1M), full conversion is reached in 1.25 h at room
temperature. The process is highly reproducible over the range of scales studied (50mg to
2.5g). 1H NMR spectroscopy showed that each oligomer was end-labeled with the initiator,
and the overlay of the GPC traces from the RI and UV detectors confirms quantitative initiation
and predictable molecular weights (see SI). Removal of the Boc groups by simple exposure of
5a–e to TFA gave oligocarbonate MoTr conjugates 6a–e in high yields from 3.
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The new MoTr conjugates 6a–e incorporate a backbone scaffold (carbonate) and side chain
spacing (1,7) previously unexplored in cell uptake studies.3 A distinguishing feature of these
molecular transporters is their stability profile; while they are stable for months as solids at
room temperature or in buffer (PBS) at ≤4°C, they degrade under physiologically relevant
conditions (Hepes buffered saline, pH 7.4) with a half-life of ~8 h at 37°C. This affords
excellent shelf stability, but also the novel ability to degrade after cellular uptake. Additionally,
the MoTrs are non-toxic at concentrations required for uptake analysis (5 min incubation,
EC50 6a=160µM; 6b=48µM, for additional toxicity and stability information see SI). Like
analogous oligoarginines, these transporters are highly water-soluble, but as shown for 6a and
6b, they readily partition into octanol when treated with sodium laurate (1.2 equiv. per charge)
(SI).17
The ability of GR oligocarbonate MoTrs 6a–c to enter cells was initially determined by flow
cytometry with Jurkat cells that had been incubated for 5 min at 23°C with the dansylated
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oligomers, washed with PBS to remove the remaining oligomers, and resuspended in PBS for
analysis (Figure 1). The uptake of 6a–c was compared to that of a dansylated octaarginine
derivative (r8, see SI for synthesis) as a positive control and the dansyl initiator 4a as a negative
control using the same 5 min pulse strategy.
The dansyl probe initiator 4a alone does not enter Jurkat cells. In striking contrast, dansyloligocarbonate conjugates 6a and 6b exhibited rapid and concentration-dependent uptake
similar to that of the dansylated r8 positive control. The extended oligomer 6c showed uptake
but also cell-cell adhesion behavior and was excluded from further analysis (SI). The significant
increase in uptake observed for 6b relative to 6a at higher concentrations is consistent with the
increase in uptake observed for MoTrs with increasing guanidinium content (up to n=15)18
and provides further evidence that the GR-oligocarbonates are functionally analogous to
oligoarginines.
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Not unlike the behavior of other GR MoTrs, the uptake of 6a and 6b was drastically decreased
when cells were incubated with modified PBS in which all sodium ions were replaced with
potassium ions (Figure 1), a protocol used to decrease the voltage potential across the cell
membrane.17 Additionally, incubating cells with NaN3, conditions known to interfere with
ATP dependent processes,19 led to a decrease in uptake (SI). Finally, decreased uptake (18–
37%) was observed with cells incubated at 4°C, suggesting a mixed mechanistic pathway in
which endocytosis could play a role (SI).20
In addition to flow cytometry studies, fluorescence microscopy using a two-photon excitation
method established that both 6a and 6b were internalized into Jurkat cells upon incubation for
5 minutes at 23°C (Figure 2).
To further probe the ability of the oligocarbonate MoTrs to function as delivery vectors,
experiments examining the delivery of the bioluminescent small molecule luciferin were
conducted. In this recently introduced assay,21 the ability of a conjugate to enter cells and
release its luciferin cargo is measured by the light emitted when luciferin is converted by
luciferase to oxyluciferin and a photon of detectable light. Only free luciferin is measured and
the analysis is independent of the mechanism(s) of entry, providing a real-time measure of
drug/probe availability. A new strategy to access thiol-terminated oligomers 6d and 6e
(Scheme 1, SI) enabled the facile synthesis of disulfide-releasable luciferin conjugates 7a and
7b (Figure 3). The ability of 7a and 7b to deliver luciferin into HepG2 cells expressing click
beetle luciferase was analyzed with a cooled charge-coupled device camera (photon count).
Importantly, alkylated luciferin is not a substrate for the luciferase enzyme,22 and all light
observed is therefore derived from the intracellular release and turnover of free luciferin.
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Figure 4 shows the uptake and delivery of luciferin for 7a, 7b, an analogous D-cysteine-r8
conjugate,21 and luciferin alone in Ringers (140 mM NaCl, 5 mM KCl, 10 mM HEPES, 10
mM D-glucose, 2 mM MgCl2, and 2 mM CaCl2) and high [K+] Ringers (70 mM NaCl, 75 mM
KCl, 10 mM HEPES, 10 mM D-glucose, 2 mM MgCl2, and 2 mM CaCl2) solutions, imaging
buffers which contain a variety of ions and glucose to maintain healthy cells during longer
imaging times. Following a 5 min incubation of the luciferase-expressing cells with transporter,
both oligocarbonate MoTr conjugates 7a and 7b continuously release free luciferin over a
period of about one hour. This behavior is in contrast to the r8 control, which exhibits much
faster release kinetics both in cells (over about 20 minutes, Figure 4), and when treated with
DTT in buffer, as observed by analytical HPLC analysis (see SI). The ability of these MoTrs
to release cargo over time offers several advantages, including the potential to avoid bolus
effects associated with administration of a free drug alone. The oligocarbonate MoTrs are able
to deliver free luciferin in a concentration-dependent manner (SI) that is inhibited by high
[K+] conditions associated with a diminished membrane potential. Free luciferin alone, while
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marginally cell permeable, exhibits negligible light output after a 5 min incubation. Taken
together, these data demonstrate that the novel oligocarbonate MoTrs are able to not only
penetrate the cell membranes of multiple cell types, but also efficiently deliver and release
small molecule cargos where they are available for turnover by intracellular targets.
In conclusion, an expedient one-step, metal-free oligomerization route to a new family of
MoTrs is described. This strategy enables the direct conjugation of probes and, by analogy,
drug moieties as part of the oligomerization process. The monomers could thus be used as “kit”
reagents for transporter-conjugate synthesis. Importantly, these oligocarbonate MoTrs show
low cytotoxicity and exhibit uptake comparable to or better than that of the parent
oligoarginines as determined by flow cytometry and fluorescence microscopy. In addition,
their ability to intracellularly deliver and release the bioluminescent small molecule probe
luciferin was demonstrated, confirming the intracellular availability of the free cargo to interact
with its target enzyme. The facile cellular uptake exhibited by these new MoTrs, the ease with
which short to long oligomers (and presumably mixed oligomers) can be prepared, and their
ability to degrade after uptake offer many advantages for drug/probe delivery, particularly for
biological and macromolecular cargos.
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Figure 1.

Flow cytometry determined cellular uptake of oligocarbonates 6a and 6b, dansylated-r8, and
dansyl initiator 4 in either PBS or high [K+] PBS. Jurkat cells were incubated with the various
transporters or positive and negative controls for 5 minutes at 23°C. Cell viability was >80%
as determined by propidium iodide analysis.
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Figure 2.

Fluorescence microscopy images showing internalization of 6b throughout various layers (0.9
µm wide) of a Jurkat cell (5 min incubation, 25 µM at 23°C). Panels A, G, L and O show a
series of z-cuts through the cell as illustrated in the diagram at top left (see SI for full z-cut
series).
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Figure 3.

Assay for measurement of intracellular luciferin delivery.
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Figure 4.

Observed bioluminescence from HepG2 cells expressing click beetle luciferase following a 5
minute incubation with 25µM 7a, 7b, cysr8 luciferin derivative, or luciferin alone in either
Ringers or [K+] Ringers solutions.
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Scheme 1.

Oligomerization Strategy
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